​POST FORUM SITE
ATTENDEES
​PRESENTERS
INVESTORS
SPONSORS & SUPPORTERS

​ACM Biolabs Pte Ltd. 

At ACM Biolabs we are focused on developing novel vaccines and antibodies using our proprietary artificial cell membrane ("ACM") technology. We are able to incorporate functional, folded membrane proteins into the artificial cell membranes which keep them stable, allowing them to induce a strong immune reaction. We have demonstrated efficacy via both injected and oral dosages using synthesized membrane proteins and have a growing pipeline of vaccines and antibodies.

The company is headquartered in Singapore, and has been operational since 2013

http://www.acmbiolabs.com/

Cue BioPharma, Inc. - [NASDAQ: CUE]

​Cue Biopharma is committed to bringing selective immune modulation to patients through our Cue Biologics platform. Our talented scientists are led by an experienced management team and supported by leading scientific and clinical advisors with deep expertise in the design and clinical development of protein biologics to treat cancer and autoimmune diseases. Together, we are developing novel, targeted therapies aimed at overcoming many of the challenges facing prevailing immunotherapeutics. We are headquartered in Kendall Square, Cambridge, MA.
​
​https://www.cuebiopharma.com

​eTheRNA Immunotherapies NV

eTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable and safer enhancement of the patient’s immune system than any other similar approach investigated until now.
​
http://www.etherna.be/

F-star Biotechnology Ltd. 

F-star is a clinical-stage biopharmaceutical company committed to delivering life-changing treatments to cancer patients. Through our highly efficient Modular Antibody Technology™ platform, we are building and progressing an extensive immuno-oncology pipeline of mAb²™, a novel class of disruptive bispecific antibodies designed to unlock new biology which cannot be achieved by combining monospecific drugs. F-star’s technological expertise and scientific approach have been validated through strategic partnerships with leaders in the pharma and biotech industries.
​
http://www.f-star.com/

Genocea Biosciences, Inc. - [NASDAQ:GNCA]

T cells are increasingly recognized as a critical element of the body’s protective immune response to a cancer. While traditional immunotherapy discovery methods have largely used predictive algorithms to find target antigens, we have been able to successfully leverage ATLASTM, our proprietary, high-throughput technology platform, to identify target antigens of T cells based on actual human immune responses.We are focused on using ATLAS’s superiority in neoantigen identification to develop neoantigen cancer vaccines. Neoantigens are personalized tumor mutations that are seen as ‘foreign’ by an individual’s immune system. Data published in recent years have indicated that an individual’s response to neoantigens drives checkpoint inhibitor efficacy and that it is possible to vaccinate an individual against their own neoantigens.GEN-009 is our most advanced candidate neoantigen vaccine for which we expect to initiate a Phase 1 clinical trial in the first half of 2018.  GEN-009 is an adjuvanted neoantigen peptide vaccine that is designed to direct a patient’s immune system to attack their tumor. GEN-009’s neoantigen peptides are identified by Genocea’s proprietary ATLAS platform, which recalls a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor. Following ATLAS neoantigen identification, Genocea will manufacture a personal vaccine for each patient.
​
​https://www.genocea.com

Hemispherx Biopharma, Inc. - [NYSEAMERICAN: HEB]

Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders.Hemispherx’s flagship products include Alferon N Injection® and the experimental therapeutics Ampligen®.  Ampligen® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome.  Hemispherx’s platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Because Ampligen® is experimental in nature, they are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials. The FDA approval of Alferon N Injection® is limited to the treatment of refractory or recurrent external genital warts in patients 18 years of age or older.  The Company’s Alferon® N approval in Argentina includes the use of Alferon N Injection® (under the brand name “Naturaferon”) for use in any patients who fail, or become intolerant to recombinant interferon, including patients with chronic active hepatitis C infection.The Company exclusively operates a GMP certified manufacturing facility in the United States for commercial products. 
​
http://www.hemispherx.net/

Hookipa Biotech AG

Hookipa Biotech AG is a clinical stage biotech company aiming to develop best-in-class active immunization therapies for infectious diseases and oncology.Our proprietary TheraT® and Vaxwave® platforms have shown promising abilities to elicit high neutralizing antibody responses, but also necessary levels of T cell responses, currently missing in most vaccine and therapeutic approaches. Hookipa’s vectors are not impeded by vector-neutralizing antibodies and can be administered repeatedly, providing even greater immune protection. Levels of specific T cells generated by TheraT® are unprecedented in the field and have the potential to transform active immune-therapy in cancers.We have completed the active phase of a Phase 1 trial of a Vaxwave®-based vaccine against cytomegalovirus (CMV) and are finalizing clinical development plans for TheraT® in Human Papilloma Virus (HPV)- related head and neck cancers.
​
http://hookipabiotech.com/

Immunicum AB - [STO: IMMU]

Immunicum is developing novel immuno-oncology therapies against a range of solid tumors. The approach is based on allogeneic dendritic cells that are designed to stimulate a personalized anti-tumor immune response in each patient. The Company’s lead compound, ilixadencel is currently being evaluated in clinical trials for the treatment of kidney cancer, liver cancer and gastrointestinal stromal tumors. Ilixadencel combines the best aspects of two approaches: a cell-based, cost-effective and off-the-shelf immune enhancer that when injected intratumorally is capable of triggering a highly specific and potentially long-lasting immune reaction against tumor cells throughout the body.
​
http://immunicum.se/

Immunovaccine, Inc. - [TSE: IMV]

Our technology provides the foundation of our Company and underscores the novel benefits of our product candidates across multiple therapeutic markets. Our human immune system is bombarded with countless messages and directives at any given moment. The key, we believe, is making sure that the right directives get through, safely and efficiently, to help our body do what it is already designed to do: fight serious diseases.The technology behind our unique delivery platform can help to get the messages across, by promoting the active uptake and extending the delivery time to the immune system. Our formulations provide a simple but elegant solution to delivering the right messages, and helping to make sure they are received and acted upon, by our immune system.Through partnerships with pharmaceutical and biotech leaders, we are leveraging the unique capabilities of platform to develop innovate therapies with potential to mobilize the power of the immune system in a more rapid, robust and sustained fashion. We work with a sense of purpose, using the best science and drug development practices to address urgent unmet medical needs in cancer and other diseases.With three candidates already in clinical trials and several more at the precipice, we are committed to building a company that can deliver value for our shareholders, patients and communities.
​
https://imvaccine.com/

ISA Pharmaceuticals B.V.

ISA Pharmaceuticals is a privately held company based in the Netherlands. It focuses on the development of rationally designed, fully synthetic immunotherapeutics for the treatment of cancer and persistent viral infections. ISA’s development platform is based on its proprietary SLP® (synthetic long peptide) and AMPLIVANT® technologies. The platform is broadly applicable and suitable for a multitude of targets and product opportunities.

The company has established its development platform based on insight into the exact mechanism of action and the immunopharmacology of its immunotherapeutics. Various clinical trials up to completion of Phase II have demonstrated the safety, tolerability and clinical efficacy of SLP® compounds, thereby providing proof-of-concept.

The company was founded in 2004 by Aglaia Oncology Fund with Leiden University Medical Center (LUMC) as its primary research partner.
​
http://www.isa-pharma.com/

Lycera

Lycera is a private biopharmaceutical company developing novel oral immune modulators for the treatment of autoimmune diseases and cancer. Based on successful progress of its world-class R&D platform, Lycera has advanced two programs into clinical development. Lycera’s most advanced wholly owned in cancer immunotherapy focuses on oral, selective RORγ agonists. The retinoic acid-related orphan receptor-gamma t (RORγt) is a nuclear receptor transcription factor that acts as a immune cell master control switch driving the generation and function of Th17 (helper T-cells) and Tc17 (cytotoxic) immune cells. Lycera’s clinical stage RORγ agonist, LYC-55716, combines multiple anti-tumor mechanisms into a single therapeutic by modulating gene expression to reprogram immune cells for improved function, as well as decrease immunosuppressive mechanisms.  LYC-55716 has completed Phase 1 single agent clinical studies, demonstrating a well tolerated profile, disease stabilization in a subset of patients as well as a confirmed partial response in a patient with advanced non-small cell lung cancer which did not respond to checkpoint inhibitor or combination chemotherapy.  LYC-55716 is currently in a Phase 2a study with 6 cohorts of patients with advanced solid tumors as well as in a Phase 1b combination study in non-small cell lung cancer in combination with anti-PD-1. The company is also advancing a wholly owned, oral, gut- directed ATPase modulator, designated LYC-30937-EC, for the treatment of autoimmune disease.  Additionally early stage research programs are focused on advancing differentiated oral small molecules for novel targets in immuno-oncology.  Lycera has an exclusive strategic collaboration with Celgene Corporation to advance Lycera’s proprietary pipeline for cancer and immune-mediated diseases.
​
https://lycera.com/

Madison Vaccines Incorporated

MVI is developing simple, safe, effective and economical immune-activating therapies for men with all stages of prostate cancer. MVI is a clinical stage biopharmaceutical company, founded in 2012. Focused on advancing innovative gene-based immunotherapies in three distinct stages of prostate cancer from pre-metastatic, to the start of metastases, to late-stage, castrate-resistant disease.
​
http://www.madisonvaccinesinc.com/

Medicenna Therapeutics, Corp. - [TSE: MDNA]

Our most advanced program, MDNA55, specifically targets the Interleukin-4 Receptor (IL4R), which is over-expressed by at least 20 different types of cancer affecting more than one million new cancer patients every year. Medicenna’s lead IL4-EC, MDNA55 is currently enrolling patients in a Phase 2b clinical trial for rGBM at leading brain cancer centres in the US. MDNA55 has completed 3 clinical trials in 72 patients, including 66 adults with rGBM, demonstrated compelling efficacy and obtained Fast-Track and Orphan Drug status from USFDA.Unlike most other cancer therapies, Medicenna’s IL4-ECs have the potential to purge both the tumor and the immunosuppressive tumor microenvironment (TME), offering a unique treatment paradigm for a large majority of cancer patients.Our approach to treat brain and other aggressive cancers received strong validation by a recent award of a $14.1M non-dilutive grant from the Cancer Prevention and Research Institute of Texas (CPRIT).The treatment plan for the MDNA55 clinical trial includes our IL4R targeted drug MDNA55, precision image-guided convection enhanced delivery (CED) and real-time monitoring of drug distribution to ensure optimal delivery of the drug.Treatment involves direct one-time intra-tumoral infusion of MDNA55 using CED. Image guided CED provides intra-tumoral delivery with sub-millimeter precision and real-time monitoring ensures uniform distribution of MDNA55 into the brain tumor and its infiltrative edges. We believe that this personalized approach by-passes the blood brain barrier (BBB), avoids potential systemic side effects and has the potential to reduce the risk of tumor recurrence – problems that have continued to plague this difficult to treat disease.In addition to brain cancers, the IL4R is a marker for highly aggressive forms of solid and blood tumors affecting more than a million new cancer patients every year. The IL4/IL4R bias is known to play a central role in the establishment of a robust immunosuppressive tumor micro-environment (TME), is expressed by cancer stem cells and is generally associated with poor survival outcomes. MDNA55 and Medicenna’s next generation fully human IL4-EC platform (MDNA57) have the potential to mature into an important class of treatments addressing large unmet needs in oncology.
​
​http://www.medicenna.com

Numab Therapeutics AG

We design and develop a new class of powerful therapeutics for the treatment of severe diseases. Our plug-and-play platform substantially reduces the random nature of the discovery process to predictably yield ready-to-develop multispecific biotherapeutics for chronic inflammation and cancer.
​
​http://www.numab.com/

OSE Immunotherapeutics - [EPA:OSE]

OSE Immunotherapeutics (Nantes – ISIN : FR0012127173 ; Mnemo : OSE) was created in May 2016 through the merger of OSE Pharma, an immuno-oncology company developing specific immunotherapy activating T lymphocytes, and Effimune, a biotechnology company specializing in immune regulation with clinical applications in autoimmunity, transplantation and immuno-oncology.OSE Immunotherapeutics is a biotechnology company dedicated to the development of innovative immunotherapies which act on effector and suppressor cells to stimulate or inhibit the body’s immune response, and to restore immune disorders in the fields of immuno-oncology, autoimmune diseases and transplantation.These new generation products are optimized to better target key receptors of the immune response’s activation or regulation, thus allowing for longer therapeutic effects.OSE Immunotherapeutics is specialized in the immune system regulation and activation technologies. The company relies upon its international and complementary team of experts involved in the research and optimisation of drug candidates, pharmaceutical development and drug registration.
​
​http://ose-immuno.com/en/

Selecta Biosciences, Inc. - [NASDAQ:SELB]

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses. Selecta plans to combine its tolerogenic Synthetic Vaccine Particles (SVP™) to a range of biologics for rare and serious diseases that require new treatment options. The company’s current proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. SEL-212, the company’s lead candidate in Phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. Selecta’s SEL-403 product candidate, a combination therapy consisting of SVP-Rapamycin and LMB-100, recently entered a Phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. Selecta’s proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat administration. The use of SVP also holds potential in the development of vaccines and treatments for allergies and autoimmune diseases. Selecta is based in Watertown, Massachusetts.
​
http://selectabio.com/

Selvita S.A. - [WSE:SLV]

Selvita is one of the largest drug discovery companies in Europe. The company has two primary focus areas: to serve the drug discovery market as a customer centric provider of high quality, integrated drug discovery services, and as a drug discovery company engaged in the research and development of breakthrough therapies in oncology.The company was established in 2007 and currently employs over 400 scientists, among which 30% are PhDs.Selvita is headquartered in Krakow, Poland, with a second research site in Poznan, Poland and foreign offices located in Cambridge, MA and San Francisco Bay Area, in the US, as well as in Cambridge, UK .Our scientists have extensive experience in life sciences, and we offer the following:Contract chemistry servicesBiology servicesIntegrated drug discovery projectsComparative studies of biosimilar medicinal products Selvita’s laboratories are GLP and GMP-certified.Selvita’s internal R&D department focuses on oncology. The company’s most advanced R&D program is SEL24, a dual PIM/FLT3 kinase inhibitor, which has entered the clinic in March 2017, and was subsequently licensed to Menarini Group.The second most advanced program is SEL120, a first-in-class small molecule inhibitor of CDK8 with potential use in hematological malignancies, colorectal cancer and breast cancer is currently developed in partnership with The Leukemia and Lymphoma Society.Selvita Early Discovery programs include: Immunooncology platform, Epigenetic platform, program targeting metabolic abnormalities in cancer, as well as an early discovery stage programs in the area of protein kinases.The company has alliances and partnerships with more than fifty large and medium-sized pharmaceutical and biotechnology companies from USA and Europe, including R&D partnerships with Merck, H3 Biomedicine, Nodthera Therapeutics, as well as Menarini Group and The Leukemia and Lymphoma Society.Selvita is listed on the Warsaw Stock Exchange (WSE:SLV).
https://selvita.com/

TapImmune, Inc. - [NASDAQ:TPIV]

TapImmune is developing immunotherapies for a variety of cancers designed to target both tumors and metastatic disease. The company’s next-generation technology has been engineered to overcome the deficiencies of earlier cancer vaccine approaches and has the potential to be a powerful standalone therapy or part of a leading combination regimen by complementing other approved or development-stage immunotherapeutics (i.e. checkpoint inhibitors). The company’s off-the-shelf vaccines boost patients’ immune systems to comprehensively stimulate both killer T-cells and helper T-cells to destroy cancer cells, and they are designed to work with 80% of the population.TapImmune is advancing two clinical stage T-cell vaccine candidates in multiple Phase II and Phase Ib/IIa clinical trials for treating ovarian and breast cancers, including programs in ovarian cancer that will benefit from FDA Fast Track and Orphan Disease Designation. The company is working in collaboration with industry and clinical leaders including Mayo Clinic, Memorial Sloan Kettering Cancer Center, and AstraZeneca.
​
https://tapimmune.com/

Triumvira Immunologics

Triumvira Immunologics is a biotechnology company developing a novel platform for engineering T cells to attack cancers.  In order to do this, we, like others, remove white blood cells from patients, use genetic engineering to direct T cells, which are an important component of the immune system, to recognize a protein found on the surface of certain cancer cells.  We then expand these reprogrammed T cells so they can be administered back to the patient, where they will find the cancer cells and kill them.  We believe our innovative and proprietary technology, called the T cell-Antigen Coupler (or TAC), possesses advantages over other approaches because of the nature of the TAC construct.Triumvira has licensed the TAC technology from the laboratory of Jonathan Bramson, PhD, of McMaster University in Hamilton, Ontario and we are currently supporting a broad research effort in Dr. Bramson’s lab. Our team is continuing to explore the biology and potential of TAC-T cells, developing TACs against a variety of cancer targets, and scaling up the manufacturing process. Our goal is to begin human testing of TAC T cells by the end of 2017. Our team and our network of academic and industry consultants brings broad industry experience and deep scientific understanding to the TAC program.
​
http://www.triumvira.com/

VLP Therapeutics​

VLP Therapeutics was established in 2013 with a mission to create next-generation virus-like particles to transform traditional vaccine therapies. We are focusing on cancer and infectious disease vaccines. VLP Therapeutics modifies viruses to target cells in two ways: 1) delivery of substantial antigen on the surface of the virus; and 2) direct insertion of genetic material inside the virus. Our virus-like particles have proven to be highly immunogenic in multiple animal models and we anticipate being in a human trial in 2018. The company is headquartered in Gaithersburg, Maryland.

https://vlptherapeutics.com/